Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls
- 1 January 2006
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 38 (8) , 682-689
Abstract
The aim of this study was to compare the prevalence of metabolic syndrome and insulin resistance in HIV-positive patients with and without HAART and healthy HIV-negative controls. In total 357 subjects were examined: 56 HIV-positive HAART-naïve, 207 HIV-positive on HAART treatment and 94 HIV-negative controls. We measured blood pressure, abdominal circumference, weight and height, and fasting serum levels of glucose, insulin and lipids in all the subjects. The presence of lipodystrophy was assessed in the HAART-treated patients. In non-overweight subjects the prevalence of the metabolic syndrome was 15% (25 of 162) in HAART-treated patients, 2% (1 of 44) in HAART-naïve (p=0.019) and 2% (1 of 45) in controls (p=0.020). The prevalence of insulin resistance in non-overweight subjects was also higher in HAART-treated than in controls, 39% vs 18% (p=0.012) but similar to HAART-naive, 32% (p = 0.48 vs HAART, p = 0.22 vs controls). In non-overweight patients with lipodystrophy the metabolic syndrome was diagnosed in 21% and insulin resistance in 49%. In the entire HAART group 25% had the metabolic syndrome and/or insulin resistance without having lipodystrophy. We conclude that fasting glucose, HDL-cholesterol, triglycerides and blood pressure should be closely monitored in all HAART-treated patients, not only in overweighed or lipodystrophic individuals.Keywords
This publication has 24 references indexed in Scilit:
- Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjectsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Prevalence of Hypertension in HIV-Positive Patients on Highly Active Retroviral Therapy (HAART) Compared with HAART-Na ve and HIV-Negative Controls: Results from a Norwegian Study of 721 PatientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected menAIDS, 2003
- An objective case definition of lipodystrophy in HIV-infected adults: a case-control studyThe Lancet, 2003
- Chlamydia pneumoniae Serology: Importance of Methodology in Patients with Coronary Heart Disease and Healthy IndividualsJournal of Clinical Microbiology, 2001
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and LipodystrophyClinical Infectious Diseases, 2001
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Hyperproinsulinemia of Type II Diabetes Is Not Present Before the Development of HyperglycemiaDiabetes Care, 1994
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985